Takahashi-Shiga Naomi, Utsunomiya Hiroki, Miki Yasuhiro, Nagase Satoru, Kobayashi Rika, Matsumoto Mitsuyo, Niikura Hitoshi, Ito Kiyoshi, Yaegashi Nobuo
Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
Clin Cancer Res. 2009 Oct 1;15(19):6028-34. doi: 10.1158/1078-0432.CCR-09-1013. Epub 2009 Sep 29.
The metabolism and synthesis of intratumoral estrogens are thought to play a very important role in the etiology and progression of endometrial carcinoma. Aromatase is a key enzyme in the conversion of androgens to estrogens, and aromatase localization studies have reported that aromatase immunoreactivity and mRNA were detected mainly in stromal cells. However, the effect of tumor-stromal interactions on local estrogen biosynthesis in endometrial carcinomas remains largely unknown.
The endometrial carcinoma cell lines (Ishikawa and RL95-2) and breast carcinoma cell line (MCF-7) were cocultured with stromal cells isolated from endometrial carcinomas, and aromatization activity was measured using liquid chromatography-tandem mass spectrometry. We then confirmed the local biosynthesis of estrogens and tumor-stromal interactions on aromatase activity in Ishikawa and RL95-2 cells. In addition, we also examined the effects of aromatase inhibitors on cell proliferation.
Aromatase activity was significantly higher in cocultures with Ishikawa or RL95-2 than in each monoculture, respectively. Estrone (E(1)) concentrations were significantly higher than estradiol (E(2)) concentrations in Ishikawa and RL95-2 cells, whereas E(2) was significantly higher than E(1) in MCF-7 cells. Cell proliferation was significantly inhibited in Ishikawa and RL95-2 cell cultures treated with aromatase inhibitors compared with control cultures.
These results indicate the contribution of not only E(2) but also E(1) to cancer cell proliferation in endometrial carcinoma. Our study may provide important information on metabolism and synthesis of intratumoral estrogens with regard to the etiology and progression of endometrial carcinoma, thus helping to achieve improved clinical responses in patients with endometrial carcinoma, who are treated with aromatase inhibitors.
肿瘤内雌激素的代谢和合成被认为在子宫内膜癌的病因学和进展中起着非常重要的作用。芳香化酶是雄激素转化为雌激素的关键酶,芳香化酶定位研究报告称,芳香化酶免疫反应性和mRNA主要在基质细胞中检测到。然而,肿瘤-基质相互作用对子宫内膜癌局部雌激素生物合成的影响仍 largely 未知。
将子宫内膜癌细胞系(Ishikawa 和 RL95-2)以及乳腺癌细胞系(MCF-7)与从子宫内膜癌中分离出的基质细胞共培养,使用液相色谱-串联质谱法测量芳香化活性。然后我们证实了 Ishikawa 和 RL95-2 细胞中雌激素的局部生物合成以及肿瘤-基质相互作用对芳香化酶活性的影响。此外,我们还研究了芳香化酶抑制剂对细胞增殖的影响。
与各自的单培养相比,与 Ishikawa 或 RL95-2 共培养时芳香化酶活性显著更高。Ishikawa 和 RL95-2 细胞中雌酮(E(1))浓度显著高于雌二醇(E(2))浓度,而在 MCF-7 细胞中 E(2)显著高于 E(1)。与对照培养相比,用芳香化酶抑制剂处理的 Ishikawa 和 RL95-2 细胞培养物中细胞增殖显著受到抑制。
这些结果表明,不仅 E(2),而且 E(1)对子宫内膜癌癌细胞增殖也有作用。我们的研究可能为肿瘤内雌激素的代谢和合成提供有关子宫内膜癌病因学和进展的重要信息,从而有助于在用芳香化酶抑制剂治疗的子宫内膜癌患者中实现更好的临床反应。